Danaher Corporation $DHR Shares Bought by Guinness Asset Management LTD

Guinness Asset Management LTD boosted its position in shares of Danaher Corporation (NYSE:DHR) by 13.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 223,570 shares of the conglomerate’s stock after buying an additional 26,896 shares during the period. Guinness Asset Management LTD’s holdings in Danaher were worth $41,597,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Danaher by 1.3% in the second quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock valued at $12,004,424,000 after purchasing an additional 788,499 shares during the last quarter. Geode Capital Management LLC increased its stake in Danaher by 0.6% during the second quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock worth $2,697,800,000 after acquiring an additional 81,670 shares during the last quarter. Norges Bank purchased a new stake in Danaher in the second quarter valued at $1,979,503,000. Generation Investment Management LLP lifted its stake in shares of Danaher by 56.2% in the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after purchasing an additional 1,787,522 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Danaher by 4.0% during the 2nd quarter. Franklin Resources Inc. now owns 4,822,442 shares of the conglomerate’s stock worth $952,625,000 after purchasing an additional 186,357 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Jefferies Financial Group upped their target price on shares of Danaher from $255.00 to $265.00 and gave the company a “buy” rating in a research report on Wednesday, January 28th. JPMorgan Chase & Co. upped their price objective on shares of Danaher from $270.00 to $275.00 and gave the stock an “overweight” rating in a report on Thursday, January 29th. The Goldman Sachs Group dropped their target price on shares of Danaher from $270.00 to $265.00 and set a “buy” rating for the company in a report on Thursday, January 29th. Leerink Partners upped their price target on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research note on Friday, January 16th. Finally, Robert W. Baird set a $251.00 price target on Danaher in a research report on Thursday, January 29th. Twenty equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $252.32.

Insiders Place Their Bets

In other news, Director Teri List sold 3,298 shares of Danaher stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the sale, the director owned 20,762 shares in the company, valued at approximately $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 30,248 shares of company stock valued at $6,609,663. 11.10% of the stock is currently owned by insiders.

Danaher Stock Down 1.7%

Shares of NYSE DHR opened at $215.70 on Friday. The stock has a market cap of $152.36 billion, a P/E ratio of 42.80, a PEG ratio of 2.97 and a beta of 0.91. The business’s fifty day simple moving average is $229.81 and its 200-day simple moving average is $214.68. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $242.80. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.35.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 28th. The conglomerate reported $2.23 EPS for the quarter, topping the consensus estimate of $2.14 by $0.09. The company had revenue of $6.84 billion during the quarter, compared to analysts’ expectations of $6.79 billion. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.14 EPS. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. As a group, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Friday, December 26th were paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date was Friday, December 26th. Danaher’s dividend payout ratio is currently 25.40%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.